William M. Mitchell Purchases 9,677 Shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) Stock

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) Director William M. Mitchell bought 9,677 shares of the stock in a transaction dated Friday, June 21st. The shares were acquired at an average price of $4.03 per share, with a total value of $38,998.31. Following the completion of the purchase, the director now directly owns 20,838 shares of the company’s stock, valued at $83,977.14. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Hemispherx BioPharma stock opened at $4.32 on Wednesday. Hemispherx BioPharma, Inc has a 1-year low of $3.62 and a 1-year high of $14.81.

Hemispherx BioPharma (NYSEAMERICAN:HEB) last announced its earnings results on Thursday, May 16th. The specialty pharmaceutical company reported ($3.08) earnings per share for the quarter.

Several analysts have recently weighed in on HEB shares. Maxim Group started coverage on Hemispherx BioPharma in a research note on Friday, June 14th. They set a “buy” rating and a $8.00 target price for the company. Ascendiant Capital Markets set a $44.00 target price on Hemispherx BioPharma and gave the company a “buy” rating in a research note on Friday, May 17th.

About Hemispherx BioPharma

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for Hemispherx BioPharma (NYSEAMERICAN:HEB)

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.